Xenetic Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed on July 8, 2015, covering events occurring on July 3, 2015. Xenetic Biosciences, Inc., a Nevada corporation, reported the completion of a financing transaction under Item 8.01 (Other Events).
Key Financial Metrics and Transaction Details
The filing details a $3 million Bridge Note financing completed with OJSC Pharmsynthez, an affiliate of the company's largest shareholder. The transaction structure includes:
- Principal Amount: $3 million.
- Instrument: 10% senior secured convertible promissory note.
- Conversion Price: $0.15 per share of common stock (at the option of Pharmsynthez).
- Warrant Terms: A common stock purchase warrant for 10 million shares at an exercise price of $0.20.
- Warrant Duration: 5 years, commencing January 1, 2016.
The filing does not provide specific values for revenue, profit, cash flow, margins, or existing debt levels outside of this new obligation.
Material Changes
The primary material change is the incurrence of new debt and the potential dilution of existing shareholders through the issuance of a convertible note and warrants. The financing was arranged directly between management and Pharmsynthez.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or a discussion of general risks. The document explicitly states that the summary provided is not a complete description of the terms and directs investors to review the attached exhibits (10.1 through 10.7) for full details.
Investor Verification Checklist
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and the Promissory Note (Exhibit 10.2) for covenants and default provisions.
- Verify the exact number of shares currently outstanding to calculate the potential dilution impact of the $0.15 conversion price and the 10 million warrant shares.
- Confirm the status of the "senior secured" collateral pledged under the Security Agreement (Exhibit 10.4).
- Check the Press Release (Exhibit 99.1) for any additional context regarding the use of proceeds.